Drugs / EGAPTIVON PEGOL
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00432770 | Dec 2006 → Mar 2007 | thrombotic disease | Archemix Corp. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00694785 | Oct 2008 → Jun 2009 | von Willebrand disease (hereditary or acquired) | Archemix Corp. | Withdrawn | No outcome recorded |
| Phase 2 | NCT00632242 | Jan → Dec 2008 | thrombotic thrombocytopenic purpura, von Willebrand disease type 2B | Archemix Corp. | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT00742612 Comparator | Feb 2009 → Jan 2010 | carotid stenosis, intracranial embolism | Archemix Corp. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00726544 Comparator | Dec 2008 → Dec 2010 | thrombotic thrombocytopenic purpura | Archemix Corp. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EGAPTIVON PEGOL | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108339 ↗ |
| Known as | ARC1779 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00632242 ↗ |
| Action | Inhibit | “ARC1779 produced dose- and concentration-dependent inhibition of vWF activity and platelet function” PMID 18025536 ↗ Nov 2007 |
| Modality | Aptamer | “ARC1779 is a therapeutic aptamer antagonist of the A1 domain of von Willebrand Factor (vWF)” PMID 18025536 ↗ Nov 2007 |
| Route | Intravenous | “Intravenous Bolus or Intravenous Bolus Followed by Continuous Infusion Administration of ARC1779” NCT00432770 ↗ |
| Target | VWF | “ARC1779 is a therapeutic aptamer antagonist of the A1 domain of von Willebrand Factor (vWF)” PMID 18025536 ↗ Nov 2007 |